The Alzheimer's Disease Neuroimaging Initiative in the era of Alzheimer's disease treatment: A review of ADNI studies from 2021 to 2022
Year: 2023
Type: article
Abstract: The Alzheimer's Disease Neuroimaging Initiative (ADNI) aims to improve Alzheimer's disease (AD) clinical trials. Since 2006, ADNI has shared clinical, neuroimaging, and cognitive data, and biofluid samples. We used conventional search methods to identify 1459 publications from 2021 to 2022 using ADNI data/samples and reviewed 291 impactful studies. This review details how ADNI studies improved disease progression understanding and clinical trial efficiency. Advances in subject selection, detection of treatment effects, harmonization, and modeling improved clinical trials and plasma biomarkers like phosphorylated tau showed promise for clinical use. Biomarkers of amyloid beta, tau, neurodegeneration, inflammation, and others were prognostic with individualized prediction algorithms available online. Studies supported the amyloid cascade, emphasized the importance of neuroinflammation, and detailed widespread heterogeneity in disease, linked to genetic and vascular risk, co-pathologies, sex, and resilience. Biological subtypes were consistently observed. Generalizability of ADNI results is limited by lack of cohort diversity, an issue ADNI-4 aims to address by enrolling a diverse cohort.
Source: Alzheimer s & Dementia
DOI: 10.1002/alz.13449
Authors: Dallas P. Veitch, Michael W. Weiner, Melanie Miller, Paul S. Aisen, Miriam A. Ashford, Laurel A. Beckett, Robert C. Green, Danielle Harvey, Clifford R. Jack, William Jagust, Susan M. Landau, John C. Morris, Kwangsik T. Nho, Rachel Nosheny, Ozioma Okonkwo, Richard J. Perrin, Ronald C. Petersen, Monica Rivera Mindt, Andrew Saykin, Leslie M. Shaw, Arthur W. Toga, Duygu Tosun, for the Alzheimer's Disease Neuroimaging Initiative
Institutions: San Francisco VA Medical Center, Northern California Institute for Research and Education, University of California, San Francisco, University of Southern California, University of California, Davis, Broad Institute, Brigham and Women's Hospital, Harvard University, Ariadne Labs, Mayo Clinic, University of California, Berkeley, Washington University in St. Louis, Indiana University Indianapolis, Indiana University School of Medicine, Indiana University – Purdue University Indianapolis, University of Wisconsin–Madison, Fordham University, Icahn School of Medicine at Mount Sinai, University of Pennsylvania
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,000
OpenAlex ID: W4386624665